Indications for VESICARE LS:
Treatment of neurogenic detrusor overactivity in pediatric patients.
<2yrs: not established. Take once daily, followed by liquid (eg, water or milk). Base dose on body wt. ≥2yrs: 9–15kg: initially 2mL (max 4mL); >15–30kg: initially 3mL (max 5mL); >30–45kg: initially 3mL (max 6mL); >45–60kg: initially 4mL (max 8mL); >60kg: initially 5mL (max 10mL). Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: do not exceed the recommended initial dose.
VESICARE LS Contraindications:
For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.
VESICARE LS Warnings/Precautions:
Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.
VESICARE LS Classification:
VESICARE LS Interactions:
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.
Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).
Generic Drug Availability:
Tabs—30, 90; Susp—150mL